NASDAQ:LXRX Lexicon Pharmaceuticals (LXRX) Stock Price, News & Analysis → It's time to ween off Chinese lithium! (From Smallcaps Daily) (Ad) Free LXRX Stock Alerts $1.75 0.00 (0.00%) (As of 06/7/2024 08:52 PM ET) Add Compare Share Share Today's Range$1.70▼$1.7550-Day Range$1.54▼$2.2852-Week Range$0.92▼$3.73Volume1.05 million shsAverage Volume3.87 million shsMarket Capitalization$430.92 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Lexicon Pharmaceuticals alerts: Email Address Lexicon Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside185.7% Upside$5.00 Price TargetShort InterestBearish9.45% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.35Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.72) to ($0.68) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.47 out of 5 starsMedical Sector657th out of 903 stocksPharmaceutical Preparations Industry308th out of 426 stocks 3.3 Analyst's Opinion Consensus RatingLexicon Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageLexicon Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Lexicon Pharmaceuticals' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted9.45% of the outstanding shares of Lexicon Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverLexicon Pharmaceuticals has a short interest ratio ("days to cover") of 6.3.Change versus previous monthShort interest in Lexicon Pharmaceuticals has recently decreased by 0.73%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldLexicon Pharmaceuticals does not currently pay a dividend.Dividend GrowthLexicon Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LXRX. Previous Next 1.9 News and Social Media Coverage News SentimentLexicon Pharmaceuticals has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Lexicon Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for LXRX on MarketBeat in the last 30 days. This is a decrease of -87% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Lexicon Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lexicon Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.80% of the stock of Lexicon Pharmaceuticals is held by insiders.Percentage Held by Institutions74.70% of the stock of Lexicon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lexicon Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Lexicon Pharmaceuticals are expected to grow in the coming year, from ($0.72) to ($0.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lexicon Pharmaceuticals is -2.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lexicon Pharmaceuticals is -2.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLexicon Pharmaceuticals has a P/B Ratio of 4.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Lexicon Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad StocksToTradeWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made millionaire Tim Bohen is giving you an inside look at the megatrend that’s going to change everything.Discover the #1 company leading this revolution About Lexicon Pharmaceuticals Stock (NASDAQ:LXRX)Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.Read More LXRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LXRX Stock News HeadlinesJune 7 at 5:32 AM | americanbankingnews.comLexicon Pharmaceuticals (NASDAQ:LXRX) Upgraded to Sell by StockNews.comMay 29, 2024 | businesswire.comLexicon Pharmaceuticals Selects Medidata to Help Advance First Non-Opioid Drug for Neuropathic Pain in Over Two DecadesMay 29, 2024 | globenewswire.comLexicon Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2024May 28, 2024 | seekingalpha.comLexicon Pharmaceuticals: Blue Sky Aplenty, Revenue Not So MuchMay 15, 2024 | money.usnews.comLexicon Pharmaceuticals IncMay 14, 2024 | globenewswire.comNew Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA® (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection FractionMay 9, 2024 | globenewswire.comLexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024May 4, 2024 | markets.businessinsider.comOptimistic Buy Rating for Lexicon Pharmaceuticals Amid Strong Inpefa Sales Outlook and Efficient Financial ManagementMay 4, 2024 | markets.businessinsider.comLexicon Pharmaceuticals Reports Q1 Loss, Misses Revenue EstimatesMay 3, 2024 | finance.yahoo.comLexicon Pharmaceuticals Inc (LXRX) Q1 2024 Earnings Call Transcript Highlights: Navigating ...May 3, 2024 | msn.comBiomea Fusion GAAP EPS of -$1.09 misses by $0.02May 2, 2024 | finance.yahoo.comLexicon Pharmaceuticals Reports Q1 2024 Earnings: Aligns with EPS Projections Amidst Strategic ...May 2, 2024 | msn.comLXRX Stock Earnings: Lexicon Pharmaceuticals Meets EPS, Misses Revenue for Q1 2024May 2, 2024 | globenewswire.comLexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 1, 2024 | msn.comLeerink Partners Initiates Coverage of Lexicon Pharmaceuticals (LXRX) with Outperform RecommendationApril 30, 2024 | markets.businessinsider.comLexicon Pharmaceuticals CEO Lonnel Coats To RetireApril 29, 2024 | finanznachrichten.deLexicon Pharmaceuticals, Inc.: Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon PharmaceuticalsApril 29, 2024 | marketwatch.comLexicon Pharmaceuticals Chief Executive Lonnel Coats to Retire in JulyApril 29, 2024 | globenewswire.comLonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon PharmaceuticalsApril 29, 2024 | finance.yahoo.comLexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 2, 2024April 23, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Alvotech (ALVO), Cardinal Health (CAH)April 18, 2024 | globenewswire.comLexicon Pharmaceuticals to Host 2024 Investor DayApril 3, 2024 | finance.yahoo.comLexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceMarch 25, 2024 | globenewswire.comClinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & ExpoMarch 16, 2024 | finance.yahoo.comLXRX Apr 2024 5.000 putSee More Headlines Receive LXRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lexicon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today6/10/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:LXRX Previous SymbolNASDAQ:LEXG CUSIP52887210 CIK1062822 Webwww.lexpharma.com Phone(281) 863-3000Fax281-863-8010Employees285Year Founded1995Price Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+185.7%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-177,120,000.00 Net Margins-8,311.12% Pretax Margin-8,376.55% Return on Equity-108.54% Return on Assets-61.97% Debt Debt-to-Equity Ratio0.35 Current Ratio15.58 Quick Ratio15.56 Sales & Book Value Annual Sales$1.20 million Price / Sales359.10 Cash FlowN/A Price / Cash FlowN/A Book Value$0.38 per share Price / Book4.61Miscellaneous Outstanding Shares246,240,000Free Float229,493,000Market Cap$430.92 million OptionableOptionable Beta1.38 Social Links 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesMr. Lonnel Coats (Age 59)CEO & Director Comp: $1.14MMr. Jeffrey L. Wade J.D. (Age 59)President & CFO Comp: $752.05kMr. Brian T. Crum (Age 51)Senior VP, General Counsel & Secretary Comp: $596.48kDr. Alan J. Main Ph.D. (Age 70)Executive Vice President of Innovation & Chemical Sciences Comp: $576.96kDr. Craig B. Granowitz M.D. (Age 59)Ph.D., Senior VP & Chief Medical Officer Comp: $652.48kMs. Kristen L. Alexander (Age 56)Vice President of Finance & Accounting Ms. Lisa M. DeFrancesco (Age 44)Head of Investor Relations & Corporate Strategy Mr. Dixon TerryVice President of ComplianceMs. Carrie SiragusaVice President of MarketingMs. Desiree GendronVice President of Sales & TrainingMore ExecutivesKey CompetitorsAVEO PharmaceuticalsNASDAQ:AVEORezoluteNASDAQ:RZLTSierra OncologyNASDAQ:SRRADynavax TechnologiesNASDAQ:DVAXLigand PharmaceuticalsNASDAQ:LGNDView All CompetitorsInsiders & InstitutionsVirtu Financial LLCBought 43,591 shares on 5/20/2024Ownership: 0.018%BVF Inc. ILSold 22,748,708 shares on 5/16/2024Ownership: 0.685%Boulder Hill Capital Management LPBought 256,400 shares on 5/14/2024Ownership: 0.104%Vanguard Group Inc.Bought 420,854 shares on 5/10/2024Ownership: 2.600%SG Americas Securities LLCSold 24,524 shares on 5/7/2024Ownership: 0.008%View All Insider TransactionsView All Institutional Transactions LXRX Stock Analysis - Frequently Asked Questions Should I buy or sell Lexicon Pharmaceuticals stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lexicon Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" LXRX shares. View LXRX analyst ratings or view top-rated stocks. What is Lexicon Pharmaceuticals' stock price target for 2024? 3 brokerages have issued twelve-month target prices for Lexicon Pharmaceuticals' shares. Their LXRX share price targets range from $5.00 to $5.00. On average, they expect the company's share price to reach $5.00 in the next year. This suggests a possible upside of 185.7% from the stock's current price. View analysts price targets for LXRX or view top-rated stocks among Wall Street analysts. How have LXRX shares performed in 2024? Lexicon Pharmaceuticals' stock was trading at $1.53 on January 1st, 2024. Since then, LXRX shares have increased by 14.4% and is now trading at $1.75. View the best growth stocks for 2024 here. When is Lexicon Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our LXRX earnings forecast. How were Lexicon Pharmaceuticals' earnings last quarter? Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) released its earnings results on Thursday, May, 2nd. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by $0.02. The biopharmaceutical company earned $1.13 million during the quarter, compared to analyst estimates of $1.17 million. Lexicon Pharmaceuticals had a negative trailing twelve-month return on equity of 108.54% and a negative net margin of 8,311.12%. What ETF holds Lexicon Pharmaceuticals' stock? Virtus LifeSci Biotech Products ETF holds 293,092 shares of LXRX stock, representing 2.55% of its portfolio. What is Lonnel Coats' approval rating as Lexicon Pharmaceuticals' CEO? 9 employees have rated Lexicon Pharmaceuticals Chief Executive Officer Lonnel Coats on Glassdoor.com. Lonnel Coats has an approval rating of 100% among the company's employees. This puts Lonnel Coats in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Lexicon Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Lexicon Pharmaceuticals investors own include Portola Pharmaceuticals (PTLA), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Dynavax Technologies (DVAX), MannKind (MNKD), ImmunoGen (IMGN), Geron (GERN), Micron Technology (MU), TherapeuticsMD (TXMD) and Gilead Sciences (GILD). Who are Lexicon Pharmaceuticals' major shareholders? Lexicon Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (2.60%), Pinnacle Associates Ltd. (0.71%), BVF Inc. IL (0.69%), GSA Capital Partners LLP (0.12%), Boulder Hill Capital Management LP (0.10%) and BNP Paribas Financial Markets (0.02%). Insiders that own company stock include International SCA Artal, Jeffrey L Wade, Lonnel Coats, Raymond Debbane and Wendy Mcdermott. View institutional ownership trends. How do I buy shares of Lexicon Pharmaceuticals? Shares of LXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LXRX) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexicon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexicon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.